The role of Recombinant interleukin-2 in the treatment of patients with chronic hepatitis B.

Cover Page

Cite item

Full Text

Abstract

Dysregulated immune response occurring in chronic hepatitis B prevents the virus elimination and contributes to progression of the infectious process. The aim of the study was to evaluate the effectiveness (biochemical, immunological, virological) of combination treatment with tenofovir and Recombinant interleukin-2 in chronic hepatitis B patients.

Material and methods. A comparative analysis of the results from laboratory examination of chronic hepatitis B patients in two comparison groups, comparable in sex, age, stage of fibrosis, viral load, was carried out: group I (n = 27) received tenofovir, according to the accepted recommendations, and recombinant interleukin-2 (rIL-2), group II (n = 25) — tenofovir.

Results. Before the onset of antiviral therapy all patients with chronic hepatitis B had increased hepatic transaminases, alkaline phosphatase and gammaglutamyl transpeptidase from 1.2 to 5 norms as well as dysregulated cellular immunity factors with significantly decreased absolute count of CD4+, CD8+, CD16+ and increased CD20+ lymphocytes. After 12 months of treatment, patients in observation groups showed normalized cytolysis and cholestasis with insignificant intergroup differences. The level of absolute count of CD4+, CD8+ T-cells and CD16+ lymphocytes in the I group increased (by 24.7%, 24.1%, 34.5%, respectively, all p < 0.001 relative to the initial values), not observed in comparison group. The level of CD20+ lymphocytes in group 1 was decreased by 35.9%, and in group 2 — by 7.9% (pI–II < 0.001). In group 1, the level of HBsAg after 12 months of treatment became lower by 52% (p < 0.001).

Conclusion. The conducted pilot study showed that the combination etiopathogenetic therapy of patients with chronic hepatitis B using tenofovir and rIL-2 improves liver functional state, restores the disturbed balance of immunocompetent cells: by increasing level of CD4+, CD8+ T-lymphocytes, CD16+ lymphocytes and reducing the count of CD20+ cells, and also allows to steadily reduce blood serum HBsAg level.

About the authors

Anastasiya F. Novikova

Samara State Medical University

Author for correspondence.
Email: a.f.novikova@samsmu.ru
ORCID iD: 0000-0002-7067-9069
SPIN-code: 1744-3938

PhD (Medicine), Assistant Professor, Depaftment of Infectious Diseases with Epidemiology

Russian Federation, Samara

Larisa L. Popova

Samara State Medical University

Email: ll_popova@mail.ru
ORCID iD: 0000-0003-0549-361X

DSc (Medicine), Professor, Professor of the Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

Dmitrii Yu. Konstantinov

Samara State Medical University

Email: d.u.konstantinov@samsmu.ru
ORCID iD: 0000-0002-6177-8487

DSc (Medicine), Associate Professor, Head of Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

References

  1. Абдурахманов Д.Т. Хронический гепатит B и D. М.: ГЭОТАР-Медиа, 2010. 288 с. [Abdurahmanov D.T. Chronic hepatitis B and D. Moscow: GEOTAR-Media, 2010. 288 p. (In Russ.)]
  2. ВОЗ. Гепатит B. [WHO. Hepatitis B (In Russ.)] URL: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-b (09.07.2021)
  3. Зайцева Е.А., Попова Л.Л., Константинов Д.Ю. Динамика отдельных показателей цитокинового спектра у больных с HBeAG-негативным гепатитом В на фоне проведения противовирусной терапии // Уральский медицинский журнал. 2017. № 1 (145). С. 73–77. [Zayceva E.A., Popova L.L., Konstantinov D.Y. The individual dynamics of the cytokine spectrum in patients with HBEAG-negative chronic hepatitis B on the background of antiviral therapy. Ural’skii meditsinskii zhurnal = Ural Medical Journal, 2017, no. 1 (145), pp. 73–77. (In Russ.)]
  4. Зайцева Е.А., Попова Л.Л., Константинов Д.Ю., Недугов Г.В. Новые возможности прогнозирования исходов противовирусной терапии у больных хроническим гепатитом В // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2018. № 3. C. 47–50. [Zaitseva E.A., Popova L.L., Konstantinov D.Y., Nedugov G.V. New possibilities of predicting the outcomes of antiviral therapy in patients with chronic hepatitis B. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy = Epidemiology and Infectious Diseases. Current Items, 2018, no. 3, pp. 47–50. (In Russ.)] doi: 10.18565/epidem.2018.3.47-50
  5. Константинова Е.А., Константинов Д.Ю., Попова Л.Л. Роль иммуноопосредованной терапии при рецидиве HBeAg-негативного гепатита В // Поликлиника. 2015. № 1-1. С. 18–20. [Konstantinova E.A., Konstantinov D.Yu., Popova L.L. The role of immune-mediated therapy in relapsed HBEAG-negative hepatitis B. Poliklinika = Polyclinic, 2015, no. 1-1, pp. 18–20. (In Russ.)]
  6. Патент № 2365381 Российская Федерация, МПК A61K 38/20 (2006.01), A61P 1/16 (2006.01), A61K 38/21 (2006.01). Способ лечения хронического вирусного гепатита В. № 2006145918/14; заявлено 22.12.2006: опубликовано : 27.08.2009 / Попова Л.Л., Мельникова Е.А., Смирнов М.Н., Суздальцев А.А., Юрченко Н.Г., Константинов Д.Ю. Патентообладатель: Государственное образовательное учреждение высшего профессионального образования «Самарский государственный медицинский университет». 6 с. [Patent No. 2365381 Russian Federation, Int. Cl. A61K 38/20 (2006.01), A61P 1/16 (2006.01), A61K 38/21 (2006.01). Method of chronic virus hepatitis B treatment. No. 2006145918/14; application: 22.12.2006: date of publication 27.08.2009 / Popova L.L., Mel’nikova E.A., Smirnov M.N., Suzdal’tsev A.A., Yurchenko N.G., Konstantinov D.Yu. Proprietors: Gosudarstvennoe obrazovatel’noe uchrezhdenie vysshego professional’nogo obrazovanija “Samarskij gosudarstvennyj meditsinskij universitet”. 6 p. (In Russ.)]
  7. Попова Л.Л. Применение ронколейкина в противорецидивной терапии хронического вирусного гепатита С // Эпидемиология и инфекционные болезни. 2007. № 5. С. 57–60. [Popova L.L. Use of roncoleukin in the antirecurrent therapy of chronic viral gepatitis C. Epidemiologiya i infektsionnye bolezni = Epidemiology and Infectious Diseases, 2007, no. 5, pp. 57–60. (In Russ.)]
  8. Akbar S.M.F., Yoshida O., Hiasa Y. Immune therapies against chronic hepatitis B. J. Gastroenterol., 2022, vol. 57, no. 8, pp. 517–528. doi: 10.1007/s00535-022-01890-8
  9. Arasli M., Ustundag Y., Delikanli B., Harmandar F., Buyukuysal C. Peripheral blood lymphocyte dynamics and viral kinetics in patients with chronic active hepatitis B virus infection treated by tenofovir. Hepatogastroenterology, 2012, vol. 59, no. 115, pp. 851–857. doi: 10.5754/hge11580
  10. Boni C., Laccabue D., Lampertico P., Giuberti T., Viganò M., Schivazappa S., Alfieri A., Pesci M., Gaeta G.B., Brancaccio G., Colombo M., Missale G., Ferrari C. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology, 2012, vol. 143, no. 4, pp. 963–973.e9. doi: 10.1053/j.gastro.2012.07.014
  11. Czaja A.J. Exploring the pathogenic role and therapeutic implications of interleukin 2 in autoimmune hepatitis. Dig. Dis. Sci., 2021, vol. 66, no. 8, pp. 2493–2512. doi: 10.1007/s10620-020-06562-2
  12. Duan S.P., Zhu L.H., Hou L.J., Wang H.W., Zhu X.W., Hao J. [Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+ T cells function in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi, 2021, vol. 29, no. 5, pp. 421–426. (In Chinese). doi: 10.3760/cma.j.cn501113-20191113-00420
  13. He J., Zhang R., Shao M., Zhao X., Miao M., Chen J., Liu J., Zhang X., Zhang X., Jin Y., Wang Y., Zhang S., Zhu L., Jacob A., Jia R., You X., Li X., Li C., Zhou Y., Yang Y., Ye H., Liu Y., Su Y., Shen N., Alexander J., Guo J., Ambrus J., Lin X., Yu D., Sun X., Li Z. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis., 2020, vol. 79, no. 1, pp. 141–149. doi: 10.1136/annrheumdis-2019-215396
  14. Meng Z., Chen Y., Lu M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front. Immunol., 2020, vol. 10: 3127. doi: 10.3389/fimmu.2019.03127
  15. Mitra S., Leonard W.J. Biology of IL-2 and its therapeutic modulation: mechanisms and strategies. J. Leukoc. Biol., 2018, vol. 103, no. 4, pp. 643–655. doi: 10.1002/JLB.2RI0717-278R
  16. Paccoud O., Surgers L., Lacombe K. Infection par le virus de l’hépatite B: histoire naturelle, manifestations cliniques et principes thérapeutiques. Rev. Med. Interne., 2019, vol. 40, no. 9, pp. 590–598. doi: 10.1016/j.revmed.2019.03.333
  17. Pal S., Dey D., Chakraborty B.C., Nandi M., Khatun M., Banerjee S., Santra A., Ghosh R., Ahammed S.M., Chowdhury A., Datta S. Diverse facets of MDSC in different phases of chronic HBV infection: impact on HBV-specific T-cell response and homing. Hepatology, 2022, vol. 76, no. 3, pp. 759–774. doi: 10.1002/hep.32331
  18. Pang X., Zhang L., Liu N., Liu B., Chen Z., Li H., Chen M., Peng M., Ren H., Hu P. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. Clin. Exp. Immunol., 2020, vol. 202, no. 1, pp. 80–92. doi: 10.1111/cei.13486
  19. Qi W., Wang Y., Huang G., Wang K. Interleukin-2 promotes pegylated interferon alpha for hepatitis B surface antigen loss: a retrospective pragmatic clinical study at the Fourth Affiliated Hospital of Zhejiang University Medical College. Health Sci. Rep., 2022, vol. 5, no. 6: e932. doi: 10.1002/hsr2.932
  20. Rivino L., Le Bert N., Gill U.S., Kunasegaran K., Cheng Y., Tan D.Z., Becht E., Hansi N.K., Foster G.R., Su T.H., Tseng T.C., Lim S.G., Kao J.H., Newell E.W., Kennedy P.T., Bertoletti A. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J. Clin. Invest., 2018, vol. 128, no. 2, pp. 668–681. doi: 10.1172/JCI92812
  21. Shao M., He J., Zhang R., Zhang X., Yang Y., Li C., Liu X., Sun X., Li Z. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus. J. Interferon Cytokine Res., 2019, vol. 39, no. 2, pp. 117–124. doi: 10.1089/jir.2018.0016
  22. Tülek N., Saglam S.K., Saglam M., Türkyilmaz R., Yildiz M. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection. Hepatogastroenterology, 2000, vol. 47, no. 33, pp. 828–831.
  23. Wang D., Fu B., Shen X., Guo C., Liu Y., Zhang J., Sun R., Ye Y., Li J., Tian Z., Wei H. Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy. Signal. Transduct. Target. Ther., 2021, vol. 6, no. 1: 376. doi: 10.1038/s41392-021-00776-0
  24. Tsukuda S., Watashi K. Hepatitis B virus biology and life cycle. Antiviral. Res., 2020, vol. 182: 104925. doi: 10.1016/j.antiviral.2020.104925
  25. Wu D., Wang P., Han M., Chen Y., Chen X., Xia Q., Yan W., Wan X., Zhu C., Xie Q., Jiang J., Wei L., Tan D., Dou X., Yu Y., Hou J., Luo X., Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol. Int., 2019, vol. 13, no. 5, pp. 573–586. doi: 10.1007/s12072-019-09956-1
  26. Wu J., Han M., Li J., Yang X., Yang D. Immunopathogenesis of HBV Infection. Adv. Exp. Med. Biol., 2020, vol. 1179, pp. 71–107. doi: 10.1007/978-981-13-9151-4_4
  27. Zhao F., Xie X., Tan X., Yu H., Tian M., Lv H., Qin C., Qi J., Zhu Q. The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis. Front. Immunol., 2021, vol. 12: 691766. doi: 10.3389/fimmu.2021.691766
  28. Zhu M.E., Wang Q., Zhou S., Wang B., Ke L., He P. Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19. Exp. Ther. Med., 2021, vol. 21, no. 3: 227. doi: 10.3892/etm.2021.9658
  29. Zhu W., Liu H., Zhang X. Toward curative immunomodulation strategies for chronic hepatitis B virus infection. ACS Infect. Dis., 2019, vol. 5, no. 5, pp. 703–712. doi: 10.1021/acsinfecdis.8b00297

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Novikova A.F., Popova L.L., Konstantinov D.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).